Lunai Bioworks, Inc. to acquire Neurobridge IP Holdings Incorporated

Lunai Bioworks, Inc. has agreed to acquire Neurobridge IP Holdings Incorporated in a strategic acquisition valued at USD 20 million. The transaction, announced on 27 April 2026, was completed on 1 May 2026. Consideration was provided entirely through shares, with both entities operating within the US healthcare sector. The deal structure involved a direct purchase of the target company by the buyer, finalising the transfer of ownership without any reported debt or cash components.

The agreement represents a significant consolidation within the domestic healthcare landscape, bringing the target's intellectual property under the ownership of the acquiring firm. Both parties are based in the United States, facilitating a straightforward regulatory environment for the transaction. The deal has now been fully executed, marking the conclusion of the acquisition process. The transaction is subject to regulatory approval.